Comparative Pharmacology
Head-to-head clinical analysis: DEXONE 0 75 versus NEOMYCIN SULFATE TRIAMCINOLONE ACETONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXONE 0 75 versus NEOMYCIN SULFATE TRIAMCINOLONE ACETONIDE.
DEXONE 0.75 vs NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexamethasone is a potent glucocorticoid that binds to glucocorticoid receptors, modulating gene expression to inhibit pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-α) and reduce inflammation, immune response, and adrenal function.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Triamcinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, thereby decreasing prostaglandin and leukotriene synthesis, and exerts anti-inflammatory, antipruritic, and vasoconstrictive effects.
0.75 mg orally once daily, typically as part of a tapering regimen for anti-inflammatory or immunosuppressive effects.
Topical: Apply thin film to affected area 2-4 times daily. Otic: Instill 3-4 drops into ear canal 2-3 times daily. Not for systemic use.
None Documented
None Documented
Terminal elimination half-life: 36-54 hours in adults with normal renal function; prolonged to 72-168 hours in severe renal impairment.
Neomycin: 2-3 hours (normal renal function); in renal impairment, prolonged up to 12-24 hours. Triamcinolone acetonide: 2-5 hours (terminal).
Renal: ~65-80% as unchanged drug; Fecal: ~10-15% as metabolites; Minor biliary excretion.
Neomycin: >90% orally administered excreted unchanged in feces; absorbed fraction (3-6%) excreted renally with 50% within 24 hours. Triamcinolone acetonide: primarily hepatic metabolism, renal excretion of metabolites (~40% as 11-keto derivatives), fecal excretion ~20%.
Category C
Category D/X
Corticosteroid
Corticosteroid